The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive
intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

The persistence of cancer cells resistant to therapy remains a major clinical challenge. In
triple-negative breast cancer, resistance to chemotherapy results in the highest recurrence …

Ferroptosis, a unique modality of cell death with mechanistic and morphological differences
from other cell death modes, plays a pivotal role in regulating tumorigenesis and offers a …

Features of the cancer epigenome distinguish cancers from their respective cell of origin and
establish therapeutic vulnerabilities that can be exploited through pharmacologic inhibition …

Methylation of cytosine in CpG dinucleotides and histone lysine and arginine residues is a
chromatin modification that critically contributes to the regulation of genome integrity …

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the
worst prognosis and few effective therapies. Here we identified MS023, an inhibitor of type I …

Bulk sequencing methodologies have allowed us to make great progress in cancer
research. Unfortunately, these techniques lack the resolution to fully unravel the epigenetic …

Triple negative breast cancer (TNBC) is a deadly form of breast cancer due to the
development of resistance to chemotherapy affecting over 30% of patients. New …